Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Mar 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Taxi ROADmAP trial is studying ways to help overweight and obese taxi and for-hire vehicle drivers improve their health through better diet and physical activity. This trial focuses on drivers in New York City, a group that often faces challenges like long hours of sitting and limited access to healthy food options. Researchers want to find the most effective and cost-efficient ways to support these drivers in losing weight and adopting healthier lifestyles. The study will involve different behavior change strategies based on proven theories, and will recruit drivers through health fairs and online platforms.
To join the trial, participants must be at least 21 years old, work full-time as a taxi or ride-share driver for at least six months, and have a body mass index (BMI) that classifies them as overweight or obese. They should also own a cell phone that can receive text messages. If selected, participants can expect to engage in activities designed to help them make healthier choices related to diet and exercise over a period of several months. The trial not only aims to support the drivers but also seeks to understand how to implement these interventions on a larger scale for similar communities.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For COMIDA participants only:
- • Self-Identifies as Mexican American or Mexican
- • Seeking services at the VDS of the Mexican Consulate
- • Prefers to speak in Spanish
- • All adults at least 18 years of age
- • Screens as obese (an adult who has a Body Mass Index (BMI) 30 or higher) or overweight (an adult who has a BMI between 25 - 29.9)
- • Agrees to be audio recorded
- For SANOS focus group participants only:
- • Self-identifies as Hispanic/Latino;
- • Seeking services at VDS or VDS Mobile;
- • Prefers to speak in Spanish;
- • At least 18 years of age;
- • Screens as obese (BMI ≥ 30 kg/m\^2) or overweight (BMI of 25 - 29.9 kg/m\^2);
- • Agrees to be audio recorded
- For SANOS RCT participants only:
- • Self-identifies as Hispanic/Latino;
- • Seeking services at VDS or VDS Mobile;
- • Prefers to speak in Spanish;
- • At least 18 years of age;
- • Screens as obese (BMI ≥ 30 kg/m\^2) or overweight (BMI of 25 - 29.9 kg/m\^2);
- • Owns a cell phone capable of receiving text messages;
- • Agrees to be audio recorded
- For Family COMIDA participants only:
- • Self-Identifies as Hispanic/Latino
- • Seeking services at the VDS (or has used VDS services in the past) of the Mexican - Consulate or VDS Mobile
- • Prefers to speak in Spanish
- • At least 18 years of age
- • Has at least one child under age 18 living in the same household
- • Owns a cell phone capable of receiving text messages
- • Willing to receive text messages (3 texts per week for 3 months)
- • Owns an internet connected device (eg, cell phone, tablet, etc) capable of conducting teleconference calls (eg, Zoom)
- For ROADmAP RCT participants only:
- • At least 21 years of age
- • Full-time (drives at least 35 hours per week) licensed taxi/FHV driver
- • Driver for at least 6 months
- • Seeking Health Fairs (or has used Health Fairs services in the past)
- • Speaks English, French, Bengali, or Spanish
- • Screens a as obese (BMI ≥ 30 kg/m2 \[≥25 kg/m2 for South Asians\]) or overweight (BMI of 25 - 29.9 kg/m2 s \[23- 24.9 kg/m2 for South Asians\])
- • (BMI cut-offs are lower for South Asians, per WHO and American Diabetes Association recommendations)
- • Owns a cell phone capable of receiving text messages
- • Agrees to be audio-recorded
- For ROADmAP Phase 2 participants only:
- • At least 21 years of age
- • Driver who participated in ROADmAP RCT or manager at a taxi garage, Uber, Lyft or driver serving/union/organization
- • Agrees to be audio-recorded
- Exclusion Criteria:
- For COMIDA participants only:
- • Will not be in the NYC area for the study duration (3-4 months) Is pregnant or might be pregnant
- • Lactating women
- • Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)
- • Has dietary restrictions (i.e. liquid diet)
- • Does not have a phone that accepts text messages or unwilling to accept text messages
- • Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional"s judgment
- • Has another family member already enrolled in COMIDA (as determined by patient report)
- For SANOS focus group participants only:
- • Is pregnant or might be pregnant; lactating women;
- • Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate);
- • Has dietary restrictions (i.e. liquid diet);
- • Has a household member who has already participated (or agreed to participate);
- For SANOS RCT participants only:
- • Is pregnant or might be pregnant; lactating women; for the study duration (6 months)
- • Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); restricting diet;
- • Currently has dietary restrictions (i.e. liquid diet);
- • Has a household member who has already participated (or agreed to participate);
- • Has already participated in the study
- • Will not be in the NY Metropolitan area for the study duration (6 months) Works for or with the Mexican consulate (including employment and/or collaborative or volunteer services)
- For Family COMIDA participants only:
- • Is pregnant or might be pregnant; lactating women for the study duration (3 months)
- • Will not be in the NY Metropolitan area for the study duration (3 months) Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)
- • Has dietary restrictions (i.e. liquid diet)
- • Has another family member who has already participated in COMIDA or SANOS
- • Has already participated in the study
- • Works for or with the Mexican consulate (including employment and/or collaborative or volunteer services)
- For ROADmAP RCT participants only:
- • Is pregnant or might be pregnant; lactating women; for the study duration (12 months)
- • Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate) that may restrict diet
- • Currently has dietary restrictions (i.e. liquid diet)
- • Has a household member who has already participated (or agreed to participate)
- • Has already participated in the study
- • Will not be in the NY Metropolitan area for 6 months from study enrollment
- • Is currently taking Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity Saxenda, Victoza, Phentermine (Adipex, Lomaira), Extended-release Phentermine/Topiramate (Qsymia), Extended-release Naltrexone/Bupropion (Contrave), Plenity, Orlistat (Xenical) or Other GLP-1 receptor agonist, or any other drug to treat obesity or there is less than 7 weeks since last dosage.
- • Has undergone weight loss/bariatric surgery or is planning to undergo such surgery in the next 12 months.
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Jennifer Leng, MD, MPH
Principal Investigator
Memorial Sloan Kettering Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials